Teva Pharmaceutical Industries Limited (NYSE:TEVA) will be participating in Leerink's 2025 Global Healthcare Conference on March 12, 2025, at 8:40 AM ET. The company will be represented by CEO Richard Francis and an unidentified representative. Good morning to everyone attending.
Teva's earnings for the fourth quarter show major challenges, such as falling revenue from U.S. generics and increasing costs in the API sector, which are affecting profits. The company's branded medications, like Austedo and Uzedy, are also struggling, with Austedo's future sales possibly influenced by IRA discussions and slow growth expectations for Ajovy and Uzedy. Although Teva's experimental drug for IBD, duvakitug, has shown encouraging results in mid-stage trials, its success will depend on the outcomes of Phase 3 trials and competition in the market.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) will hold a call for investors on February 24, 2025, at 8:00 AM ET to discuss new data about Duvakitug (Anti-TL1A) presented at the ECCO Conference. The call will feature company representatives, including Christopher Stevo, Eric Hughes, and Vipul Jairath, along with participants from various financial institutions. The operator will welcome everyone to the presentation of the Phase 2b data for Duvakitug.
The last trades of the day with the Fast Money traders.
Sound Shore Management, an investment management company, has published its investor letter for the last quarter of 2024. You can download the letter here. In the fourth quarter of 2024, the fund's Investor Class (SSHFX) and Institutional Class (SSHVX) saw increases of 1.25% and 1.32%, which were lower than the 2.41% return of the Standard & Poor’s index.
On February 18, 2025, Teva Pharmaceutical Industries Ltd. announced that it will hold a conference call and live webcast on February 24, 2025, at 8 am E.T. During this event, Eric Hughes, MD, PhD, along with external experts in inflammatory bowel disease (IBD), will talk about the positive Phase 2b results for duvakitug (anti-TL1A) that were presented at the 20th Annual Congress of the European Crohn's and Colitis Organization (ECCO).
The CEO of Teva Pharmaceutical Industries from Israel stated on Monday that the administration of U.S. President Donald Trump should accelerate the approval process for generic drugs and allow certain medications to be exempt from funding freezes.
Teva Pharmaceuticals Industries Ltd, listed on the NYSE as TEVA, is the biggest manufacturer of generic drugs in the world, offering more than 500 generic and biosimilar medications. This major player in the healthcare industry also produces a range of branded drugs that contribute to its growth.
Teva Pharmaceutical Industries had impressive results in the fourth quarter of 2024, but their predictions for 2025 were disappointing, leading to a quick drop in their stock price. The company's careful outlook for 2025 may be easier to exceed, making it an attractive option for long-term investors. Teva's development projects, such as Duvakitug and various biosimilars, present strong growth opportunities, with important milestones and possible product launches expected between 2025 and 2027.
We just released a list of the 10 stocks that performed the worst on Wednesday. In this article, we will examine how Teva Pharmaceutical Industries Limited (NYSE:TEVA) ranked among these underperformers. The stock market fell on Wednesday, with all major indices ending lower, mainly due to losses in technology stocks.